![]() |
市場調查報告書
商品編碼
1618270
經導管二尖瓣瓣膜修復設備:市場洞察·競爭環境·市場預測 (~2030年)Transcatheter Mitral Valve Repair Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
根據預測,經導管二尖瓣修復裝置市場規模將從 2023 年的 11.9706 億美元成長到 2030 年的 27.5671 億美元,預測期內複合年增長率為 14.95%。
經導管二尖瓣修復裝置的市場受到心血管疾病(包括各種心臟瓣膜疾病)患病率的增加、監管許可等產品開發活動的增加以及久坐生活方式的推動,該市場正在迅速增長。
經導管二尖瓣修復裝置:市場動態
根據英國心臟基金會(BHF)報道,由於生活方式改變和老化,2022年全球約有6.4億人將患有心臟和循環系統疾病。
根據世界衛生組織2020年的數據,全球鈣化性主動脈瓣狹窄盛行率估計為900萬人。心血管疾病(包括心血管疾病和各種心臟瓣膜疾病)的盛行率不斷增加,相信會增加對經導管二尖瓣修復裝置的需求。
患者對微創手術的偏好增加也可能對預測期內的市場成長產生正面影響。與傳統手術相比,經導管二尖瓣修復裝置具有微創性,包括恢復時間更快、手術後疼痛更少、住院時間更短、傷口併發症更少以及更好的傷口假體等優點。
按類型劃分,生物瓣膜領域預計將在 2023 年佔據很大的收入佔有率。這是由於材料科學的進步、耐用性的提高和臨床應用的擴大。
源自豬和牛組織的人工瓣膜由於其優越的血流動力學性能、降低血栓形成性以及無需終生抗凝血治療而變得越來越受歡迎,這對於活躍的患者尤其有益。
本報告提供全球經導管二尖瓣瓣膜修復設備的市場調查,彙整市場概要,市場影響因素及市場機會分析,法律制度,市場規模的轉變·預測,各種區分·地區/各主要國家的詳細分析,競爭情形,主要企業簡介等資訊。
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and the increasing product developmental activities worldwide
The transcatheter mitral valve repair devices market was valued at USD 1,197.06 million in 2023, growing at a CAGR of 14.95% during the forecast period from 2024 to 2030 to reach USD 2,756.71 million by 2030. The transcatheter mitral valve repair devices market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
Transcatheter Mitral Valve Repair Devices Market Dynamics:
According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases worldwide owing to changing lifestyles, aging, and a growing population.
As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter mitral valve repair devices.
The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter mitral valve repair devices offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.
Additionally, in January 2021, Cardiovascular Systems, Inc. received CE Mark for Diamondback 360(R) Coronary Orbital Atherectomy System.
Therefore, the factors stated above collectively will drive the overall transcatheter mitral valve repair devices market growth.
However, risk and complications associated with transcatheter mitral valve repair procedures, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter mitral valve repair devices market growth.
Transcatheter Mitral Valve Repair Devices Market Segment Analysis:
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the transcatheter mitral valve repair devices market, the bioprosthetic tissue (biological) valve category is expected to have a significant revenue share in the year 2023. This is due to the advancements in material science, enhanced durability, and expanding clinical applications.
Bioprosthetic valves, derived from porcine or bovine tissue, are increasingly preferred for their superior hemodynamic performance, reduced thrombogenicity, and elimination of lifelong anticoagulation therapy, which is particularly advantageous for elderly and active patients.
Further, the increasing product launches & approvals and other strategic activities will in turn propel the demand for bioprosthetic tissue valve devices. For instance, in September 2021, Abbott received US FDA approval for Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people suffering from aortic or mitral valve disease. Epic Plus, a bioprosthetic valve, do not require long-term use of blood-thinner medication, making them the recommended option for people, especially aged over 70 years who are at risk of taking blood thinners.
Therefore the widespread uses and various features of bioprosthetic tissue (biological) valve) enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall transcatheter mitral valve repair devices market:
Among all the regions, North America is expected to dominate the transcatheter mitral valve repair devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter mitral valve repair devices market in the North America region during the forecast period from 2024 to 2030.
Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.
According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.
Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter mitral valve repair devices.
Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter mitral valve repair devices. For example, in September 2022, Edwards Lifesciences received FDA approval for its Pascal Precision system. The device used minimally invasive surgery to repair the mitral valve in patients with degenerative mitral regurgitation, a condition where the valve between heart chambers does not close completely, allowing blood to leak back through.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter mitral valve repair devices market.
Transcatheter Mitral Valve Repair Devices Market key players:
Some of the key market players operating in the transcatheter mitral valve repair devices market include Abbott, Edwards Lifesciences Corporation, Shockwave Medical, Inc., LivaNova PLC, NeoChord, Inc., Coramaze Technologies, CryoLife, Inc., JenaValve Technology, Inc., Medtronic, Boston Scientific Corporation, and others.
Recent Developmental Activities in the Transcatheter Mitral Valve Repair Devices Market:
Key Takeaways from the Transcatheter Mitral Valve Repair Devices Market Report Study
Target Audience who can be benefited from this Transcatheter Mitral Valve Repair Devices Market Report Study
Frequently Asked Questions for the Transcatheter Mitral Valve Repair Devices Market: